Rating Change
Wells Fargo analysts initiated coverage on Denali Therapeutics Inc. (NASDAQ:DNLI) with a rating of Overweight on November 13, 2026.
new coverageNASDAQ:DNLI
Wells Fargo Initiates Coverage on Denali Therapeutics Inc. (DNLI) with Overweight
Wells Fargo analysts initiated coverage on Denali Therapeutics Inc. (NASDAQ:DNLI) with a rating of Overweight on November 13, 2026.
At publication ·
What changed
Denali Therapeutics Inc. (NASDAQ:DNLI) · new coverage
- Firm
- Wells Fargo
- Rating
- Overweight
- Price at event
- $18.74
- Market capitalization
- $2.5B
At a glance
Key takeaways
- Wells Fargo initiated Overweight coverage on Denali Therapeutics (DNLI) on November 13, 2026, as the healthcare stock trades at $18.74 with a $2.5B market capitalization.
Market Context
Denali Therapeutics Inc. operates in the Healthcare sector. The stock currently trades at $18.74 with a market capitalization of $2.5B. The stock has gained 7.5% over the past 52 weeks.
Analyst coverage from Wells Fargo provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Denali Therapeutics Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Denali Therapeutics Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Nov 13, 2026 | Morgan Stanley | Overweight | N/A |
| Nov 13, 2026 | Wells Fargo | Overweight | N/A |
| Nov 04, 2026 | Morgan Stanley | Overweight | N/A |
| Nov 04, 2026 | Wedbush | Outperform | N/A |
| Nov 04, 2026 | BTIG | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View DNLI Stock Page
Frequently Asked Questions
What does the Overweight rating mean for DNLI?
A rating of Overweight from Wells Fargo reflects the analyst's outlook on Denali Therapeutics Inc. (NASDAQ:DNLI). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the DNLI forecast page.